Abstract：
Lupus remains a disease with a low prioritisation in the national agendas of many countries in Latin America, the Middle East, and Asia-Pacific, where there is a dearth of rheumatologists and limited access to new or even standard lupus treatments. There is thus an important need for education, advocacy, and outreach to prioritise lupus in these regions to ensure that patients receive the care they need. This article reviews some of the specific challenges facing the care and management of people with lupus in these regions and suggests strategies for improving patient outcomes. Specifically, we review and discuss (with a focus on the aforementioned regions) the epidemiology of lupus; economic costs, disease burden, and effects on quality of life; barriers to care related to disease assessment; barriers to effective treatment, including limitations of standard treatments, high glucocorticoid use, inadequate access to new treatments, and low adherence to medications; and strategies to improve lupus management and patient outcomes. We hope that this represents a call to action to come together and act now for the lupus community, policymakers, health authorities, and healthcare professionals to improve lupus management and patient outcomes in Latin America, the Middle East, and Asia-Pacific.
摘要：
狼疮仍然是一种在拉丁美洲许多国家的国家议程中优先级较低的疾病，中东,亚太地区，那里缺乏风湿病学家，获得新的或甚至标准的狼疮治疗的机会有限。因此，对教育有重要的需求，倡导，以及在这些地区优先考虑狼疮，以确保患者获得所需的护理。本文回顾了这些地区狼疮患者的护理和管理面临的一些具体挑战，并提出了改善患者预后的策略。具体来说,我们回顾和讨论(重点关注上述地区)狼疮的流行病学；经济成本，疾病负担,对生活质量的影响；与疾病评估相关的护理障碍；有效治疗的障碍，包括标准治疗的限制，高糖皮质激素的使用，无法获得新的治疗方法，和药物依从性低；以及改善狼疮管理和患者预后的策略。我们希望这代表着采取行动的呼吁，团结起来，现在就为狼疮社区采取行动，政策制定者，卫生当局,和医疗保健专业人员改善拉丁美洲的狼疮管理和患者预后，中东,和亚太地区。
